Annals of Surgical Oncology

, Volume 26, Issue 1, pp 131–138 | Cite as

Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults

  • Doralina L. Anghelescu
  • Christina-Lin Brown
  • Andrew J. Murphy
  • Andrew M. Davidoff
  • Paxton V. Dickson
  • Evan S. Glazer
  • Zachary E. Stiles
  • Michael W. Bishop
  • Luke Douthitt
  • Jeremiah L. DeneveEmail author
Pediatric Oncology



Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive sarcoma. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may improve survival.


A retrospective review of anesthetic management and postoperative pain control strategies after CRS/HIPEC for DSRCT from 2013 to 2017 was performed.


The review analyzed 10 CRS/HIPEC procedures performed for nine DSRCT patients with a median age of 19 years (range 10–24 years). Six of these patients were Caucasian, and seven were men. The median operative duration was 551 min (range 510–725 min), and the median anesthesia duration was 621 min (range 480–820 min). Postoperative mechanical ventilation was necessary in 5 patients for a median duration of 1 day (range 0–2 days). The median intraoperative intravenous fluid administration was 13 ml/kg/h (range 6.3–24.4 ml/kg/h), and the colloid administration was 12 ml/kg (range 0.0–53.0 ml/kg). The median blood loss was 15 ml/kg (range 6.3–77.2 ml/kg). Nine patients received intraoperative transfusion with a median red blood cell transfusion volume of 14 ml/kg (range 10.1–58.5 ml/kg). The median intraoperative urine output was 2 ml/kg/h (range 0.09–8.40 ml/kg/h), and half of the patients received intraoperative diuretics. Cisplatin was used during HIPEC for eight surgeries. Acute kidney injury was observed in two patients, one of whom required short-term dialysis. Epidural infusions were used in eight cases for a median of 4 days (range 3–5 days). Postoperative intravenous opioid use (morphine equivalent) was 0.67 mg/kg/day (range 0.1–9.2 mg/kg/day) administered for a median of 11 days (range 2–35 days).


Cytoreduction and HIPEC for DSRCT are associated with significant perioperative fluid requirements and potentially challenging pain management. Renal protective strategies should be considered for reduction of cisplatin-associated nephrotoxicity. Further investigation for a more effective, less systemically toxic HIPEC agent is warranted.



This work was supported in part by the R25CA23944 grant from the National Cancer Institute. The authors thank Lynn Wynn, Amy Kimble, and Dina Darby for care of the patients with DSRCT.


The authors declare that they have no competing interests.

Supplementary material

10434_2018_6808_MOESM1_ESM.docx (22 kb)
Supplementary material 1 (DOCX 22 kb)


  1. 1.
    Hayes-Jordan A. Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in DSRCT: progress and pitfalls. Curr Oncol Rep. 2015;17:38.CrossRefGoogle Scholar
  2. 2.
    Hayes-Jordan A, Green HL, Lin H, et al. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol. 2014;21:220–4.CrossRefGoogle Scholar
  3. 3.
    Gerald WL, Rosai J. Case 2: desmoplastic small cell tumor with divergent differentiation. Pediatr Pathol. 1989;9:177–83.CrossRefGoogle Scholar
  4. 4.
    Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol. 1996;14:1526–31.CrossRefGoogle Scholar
  5. 5.
    Hayes-Jordan A, LaQuaglia MP, Modak S. Management of desmoplastic small round cell tumor. Semin Pediatr Surg. 2016;25:299–304.CrossRefGoogle Scholar
  6. 6.
    Hayes-Jordan A, Green H, Fitzgerald N, et al. Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion. J Pediatr Surg. 2010;45:1000–6.CrossRefGoogle Scholar
  7. 7.
    Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker P. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg. 1994;94:191–7.Google Scholar
  8. 8.
    Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12:1–6.Google Scholar
  9. 9.
    Hayes-Jordan A, Green H, Lin H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. Ann Surg Oncol. 2015;22:1726–32.CrossRefGoogle Scholar
  10. 10.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefGoogle Scholar
  11. 11.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.CrossRefGoogle Scholar
  12. 12.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefGoogle Scholar
  13. 13.
    NCI. Common Terminology Criteria for Adverse Events (CTCAE). 2009;4.Google Scholar
  14. 14.
    Selewski DT, Cornell TT, Heung M, et al. Validation of the KDIGO acute kidney injury criteria in a pediatric critical care population. Intensive Care Med. 2014;40:1481–8.CrossRefGoogle Scholar
  15. 15.
    Owusu-Agyemang P, Arunkumar R, Green H, et al. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Ann Surg Oncol. 2012;19:2652–6.CrossRefGoogle Scholar
  16. 16.
    Raspe C, Flother L, Schneider R, et al. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43:1013–27.CrossRefGoogle Scholar
  17. 17.
    Colantonio L, Claroni C, Fabrizi L, et al. A randomized trial of goal-directed vs standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2015;19:722–9.CrossRefGoogle Scholar
  18. 18.
    Varadhan KK, Lobo DN. A meta-analysis of randomised controlled trials of intravenous fluid therapy in major elective open abdominal surgery: getting the balance right. Proc Nutr Soc. 2010;69:488–98.CrossRefGoogle Scholar
  19. 19.
    Abraham-Nordling M, Hjern F, Pollack J, et al. Randomized clinical trial of fluid restriction in colorectal surgery. Br J Surg. 2012;99:186–91.CrossRefGoogle Scholar
  20. 20.
    Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61–7.CrossRefGoogle Scholar
  21. 21.
    Green H, Lin H, Owusu-Agyemang P, et al. Perioperative renal protective treatment avoids renal toxicity in pediatric and adult patients undergoig HIPEC with cisplatin. J Pediatr Oncol. 2014;2:10–16.CrossRefGoogle Scholar
  22. 22.
    Thong SY, Chia CS, Ng O, et al. A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Singapore Med J. 2017;58(8):488–96.CrossRefGoogle Scholar
  23. 23.
    Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–4.CrossRefGoogle Scholar
  24. 24.
    Santoso JT, Lucci JA III, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003; 52:13–18.CrossRefGoogle Scholar
  25. 25.
    Benoehr P, Krueth P, Bokemeyer C, et al. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol. 2005;16:452–8.CrossRefGoogle Scholar
  26. 26.
    Maciver AH, Al-Sukhni E, Esquivel J, et al. Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS/HIPEC) and perioperative practices: an international survey of high-volume surgeons. Ann Surg Oncol. 2017;24:923–30.CrossRefGoogle Scholar
  27. 27.
    Osseis M, Weyrech J, Gayat E, et al. Epidural analgesia combined with a comprehensive physiotherapy program after cytoreductive surgery and HIPEC is associated with enhanced postoperative recovery and reduces intensive care unit stay: a retrospective study of 124 patients. Eur J Surg Oncol. 2016;42:1938–43.CrossRefGoogle Scholar
  28. 28.
    Schmidt C, Creutzenberg M, Piso P, et al. Perioperative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia. 2008;63:389–95.CrossRefGoogle Scholar
  29. 29.
    Bell JC, Rylah BG, Chambers RW, et al. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience. Ann Surg Oncol. 2012;19:4244–51.CrossRefGoogle Scholar
  30. 30.
    Owusu-Agyemang P, Soliz J, Hayes-Jordan A, et al. Safety of epidural analgesia in the perioperative care of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:1487–93.CrossRefGoogle Scholar
  31. 31.
    Piccioni F, Casiraghi C, Fumagalli L, et al. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. Int J Surg. 2015;16:99–106.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Doralina L. Anghelescu
    • 1
  • Christina-Lin Brown
    • 1
  • Andrew J. Murphy
    • 2
  • Andrew M. Davidoff
    • 2
  • Paxton V. Dickson
    • 3
  • Evan S. Glazer
    • 3
  • Zachary E. Stiles
    • 3
  • Michael W. Bishop
    • 4
  • Luke Douthitt
    • 5
  • Jeremiah L. Deneve
    • 3
    Email author
  1. 1.Division of Anesthesiology, Department of Pediatric MedicineSt Jude Children’s Research HospitalMemphisUSA
  2. 2.Department of SurgerySt Jude Children’s Research HospitalMemphisUSA
  3. 3.Division of Surgical Oncology, Department of SurgeryUniversity of Tennessee Health Science CenterMemphisUSA
  4. 4.Department of Medical OncologySt Jude Children’s Research HospitalMemphisUSA
  5. 5.Department of AnesthesiologyMemphis Anesthesia GroupMemphisUSA

Personalised recommendations